SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the...
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous...
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash...
Eliem Therapeutics is sashaying away from the brink of closure, joining hands with Tango after reviewing strategic alternatives.
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status...
Five months after waving goodbye to its phase-2-ready depression drug candidate and laying off 55% of staff, Eliem Therapeutics is closing its sole remaining program and assessing its “strategic alternatives.”
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability ...
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
How many years of cash runway do biotechs need to feel comfortable? Two? Three? Eliem Therapeutics has decided its two years of cash looks dicey in the current capital environment—and has responded by shelving a phase 2-ready depression drug candidate and laying off 55% of staff in a pivot to preclinical.
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition